In July 2021, based on the ORR and long-term survival benefit of by the EXCLAIM trial, mobocertinib was accepted by the Center for Drug Evaluation of the National Medical Products Administration of China, and the FDA accelerated the approval of the application of mobocertinib for EGFR ex20ins-positive NSCLC patients who had previously received platinum-based chemotherapy in September 202127,42. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.